Company intelligence / Profile preview

Suzhou Alphamab Co., Ltd.

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Suzhou Alphamab is a clinical-stage, innovation-driven biotech company specializing in biologics R&D, with a pipeline spanning hematology, oncology, endocrinology, and anti-infectives, including multiple programs in late-stage clinical trials in China[1][6]. The company has not yet reported commercialized products but has advanced candidates in pivotal studies.

Therapeutic areas: EndocrinologyInfectious DiseasesHematologyCardiovascularOncology
Modalities: Monoclonal antibodyFusion proteinNanobodyAntibody-drug conjugateBiosimilarRecombinant protein
Industry: Biotech

Drug pipeline

9 assets

lofacimig

8 more assets in the full pipeline.

Request access →

Partnerships

Shanghai Institute of Materia Medica, Chinese Academy of SciencesSoutheast UniversityThermo Scientific

Beyond the preview

Go deeper on Suzhou Alphamab Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Alphamab Co., Ltd..

Explore the full profile